FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	IVAL
OMB Number:	3235-0287
Estimated average be	urden
hours per response	. 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Daint on Tru	na Dasmanaa														
(Print or Type Responses) 1. Name and Address of Reporting Person * Almenoff June Sherie				2. Issuer Name and Ticker or Trading Symbol Avalo Therapeutics, Inc. [AVTX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O AVALO THERAPEUTICS, INC., 540 GAITHER ROAD, SUITE 400				3. Date of Earliest Transaction (Month/Day/Year) 12/31/2021								e title below)		er (specify below)
(Street) ROCKVILLE, MD 20850				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ I	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City	(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu						es Acquired,	lired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year		2A. Deemed Execution Day (Month/Day/		Date, if Co		de (.	Securities Acq A) or Disposed of Instr. 3, 4 and 5)	of (D) Own Tran	Amount of Securities I wned Following Report ransaction(s) nstr. 3 and 4)		ed	Ownership Form: E Direct (D)	7. Nature of Indirect Beneficial Ownership
							C	Code V A	amount (A) or (D)	Price				or Indirect (I) (Instr. 4)	Instr. 4)
								display	form are not r s a currently	valid OMB	control r		e form		
Derivative	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transac Code	ts, ca	5. Numb of Deriva Securi Acqui (A) or Dispon of (D)	er ative ities red sed	in this display	form are not rest a currently osed of, or Bendenvertible securisable and te	valid OMB	ned d Amount	number.	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form of Derivativ Security: Direct (D or Indirect	Benefic Owners (Instr. 4
Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	ts, ca	5. Numb of Deriva Securi Acqui (A) or Dispos	er ative ities red sed	in this display cquired, Disp nts, options, co 6. Date Exerc Expiration Da	form are not rest a currently osed of, or Bendenvertible securisable and te	eficially Own- rities) 7. Title and of Underlyi Securities	ned d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(Ownershi Form of Derivativ Security: Direct (D or Indirects) (I)	of India Benefic Owners (Instr. 4

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Almenoff June Sherie C/O AVALO THERAPEUTICS, INC. 540 GAITHER ROAD, SUITE 400 ROCKVILLE, MD 20850	X				

Signatures

/s/ Christopher R. Sullivan, by Power of Attorney	01/04/2022
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) 100% of this stock option will immediately vest on the date that it is granted.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.